Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
23 janv. 2024 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
14 déc. 2023 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
13 déc. 2023 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
17 nov. 2023 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute Reports First Quarter Fiscal 2024 Results
13 nov. 2023 16h05 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
17 oct. 2023 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
11 oct. 2023 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious...
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
14 sept. 2023 16h05 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute to Participate in Upcoming Investor Conferences in September
06 sept. 2023 07h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential...
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
27 juin 2023 16h05 HE
|
Rezolute, Inc.
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif., June 27, 2023 ...